2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human
PAPER

1425 The germline DDX41 p.M1I start-codon loss mutation results in a loss-of-function allele

Julianna Fisher, BS, Emily Stepanchick2, Andrew Wilson3, Joshua Jones4, Elizabeth Shockney5, Timothy Chlon, PhD6
1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
2 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
3 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
4 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
5 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
6 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Heterozygous germline variants of DDX41 occur in approximately 4% of adult Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) cases, making them the most prevalent cause of inherited predisposition to these diseases. DDX41 is a member of the DEAD-box RNA helicases, and is ascribed roles in pre-mRNA splicing, ribosome biogenesis, R-loop regulation, and innate immune sensing. While it is known DDX41 is required for hematopoiesis, the precise mechanism by which DDX41 mutations contribute to MDS and AML onset is poorly understood and may involve cell-type specific functions.

Most disease-associated DDX41 variants are truncating and result in the loss of full-length protein expression. However, start-codon loss mutation, p.M1I, is among the most prevalent DDX41 variants observed in recent patient cohorts accounting for 20-30% of DDX41-mutant MDS and AML cases. The p.M1I variant is predicted to cause loss of full-length protein expression but permit the expression of shorter DDX41 isoforms beginning from alternative start sites at either M127 or M132. While these shorter DDX41 isoforms are conserved in murine and human cells, their ability to maintain the required functions of DDX41 as well as the impact of the p.M1I variant on required functions of DDX41 is unknown. 

To determine the effect of the DDX41M1I on development and in vivo hematopoiesis, we generated a C57Bl/6 mouse line harboring a p.M1I mutation in the endogenous Ddx41 allele. We observed Ddx41M1I/+ mice were phenotypically normal and had normal complete blood cell counts up to 2 months of age. The HSPC function was also unaffected in competitive bone marrow transplant assays and colony formation assays, indicating heterozygous p.M1I mutation does not substantially affect hematopoiesis.

Despite screening 32 pups from multiple F2 crosses, we were unable to obtain homozygous p.M1I mice at Mendelian ratios, indicating p.M1I homozygosity causes embryonic lethality. To determine the functional impact of the p.M1I variant in the absence of wild-type DDX41, we crossed Ddx41M1I mice with Ddx41flox; Rosa26CreERT2 mice, resulting in Ddx41M1I/flox mice where the conditional allele is excised upon tamoxifen administration. In lineage-negative BM cells treated with 4-OH-tamoxifen, we observed Ddx41M1I/- cells had reduced expression of full-length Ddx41 protein compared to Ddx41+/+. Consistent with these findings, Ddx41 transcript levels were significantly reduced in Ddx41M1I/-and Ddx41-/- compared to Ddx41+/+.

To assess the effect on HSPC function, we conducted competitive bone marrow transplant assays and colony formation assays and found Ddx41M1I/- HSPC were completely non-functional. They were rapidly outcompeted in the bone marrow transplant as their chimerism dropped from 50% at time 0 to less than 10% in 16-weeks, and they formed no colonies in colony formation assays. These phenotypes were indistinguishable from Ddx41-/- HSPC in the same assays.

To define the role of the p.M1I variant in maintaining DDX41’s function as an innate immune sensor in myeloid cell subsets, we isolated lineage-negative BM cells and bone marrow derived macrophages (BMDM) from mice of the indicated genotypes. Lineage-negative cells and BMDM were stimulated synthetic double-stranded DNA, poly (dA:dT) with for 4, 8, and 12 hours and interferon beta (ifnb) expression was assessed by qPCR. Across both myeloid cell populations, ifnb expression was comparable among all genotypes, indicating that DDX41 loss does not impair type I interferons expression in response cytosolic DNA stimuli.

Notably, we did not observe an increase in the expression of shorter DDX41 isoforms in lineage-negative cells or BMDMs with the p.M1I variant, indicating that utilization of the alternative M127 or M132 start sites is not increased. We posit that this results from nonsense mediated decay, caused by an upstream out-of-frame ATG in the Ddx41 transcript. Collectively, our findings establish that p.M1I variant functions as a loss-of-function allele and promotes DDX41-mutant pathogenesis through the same mechanism as truncating variants.

Julianna Fisher, BS: No relevant conflicts of interest to declare.